Loss of Smad7 Promotes Inflammation in Rheumatoid Arthritis

Gengmin Zhou 1†, Xiaolin Sun 2†, Qingxia Qin 1, Jiyang Lv 1, Yueming Cai 1, Meiyi Wang 1, Rong Mu 2, Hui-yao Lan 3* and Qing-Wen Wang 1*

† Department of Rheumatism and Immunology, Peking University Shenzhen Hospital, Shenzhen, China, 2 Department of Rheumatology and Immunology, Peking University People’s Hospital, Peking, China, 3 Department of Medicine and therapeutics, Li KaShing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, China

Objective: Smad7 is an inhibitory Smad and plays a protective role in many inflammatory diseases. However, the roles of Smad7 in rheumatoid arthritis (RA) remain unexplored, which were investigated in this study.

Methods: The activation of TGF-β/Smad signaling was examined in synovial tissues of patients with RA. The functional roles and mechanisms of Smad7 in RA were determined in a mouse model of collagen-induced arthritis (CIA) in Smad7 wild-type (WT) and knockout (KO) CD-1 mice, a strain resistant to autoimmune arthritis induction.

Results: TGF-β/Smad3 signaling was markedly activated in synovial tissues of patients with RA, which was associated with the loss of Smad7, and enhanced Th17 and Th1 immune response. The potential roles of Smad7 in RA were further investigated in a mouse model of CIA in Smad7 WT/KO CD-1 mice. As expected, Smad7-WT CD-1 mice did not develop CIA. Surprisingly, CD-1 mice with Smad7 deficiency developed severe arthritis including severe joint swelling, synovial hyperplasia, cartilage damage, massive infiltration of CD3+ T cells and F4/80+ macrophages, and upregulation of proinflammatory cytokines IL-1β, TNFα, and MCP-1. Further studies revealed that enhanced arthritis in Smad7 KO CD-1 mice was associated with increased Th1, Th2 and, importantly, Th17 over the Treg immune response with overactive TGF-β/Smad3 and proinflammatory IL-6 signaling in the joint tissues.

Conclusions: Smad7 deficiency increases the susceptibility to autoimmune arthritis in CD-1 mice. Enhanced TGF-β/Smad3-IL-6 signaling and Th17 immune response may be a mechanism through which disrupted Smad7 causes autoimmune arthritis in CD-1 mice.

Keywords: SMAD7, RA, Th17 & Tregs cells, TGF-beta 1, inflammation immunomodulation

INTRODUCTION

Rheumatoid arthritis (RA) is an autoimmune disease with chronic inflammation, synovial hyperplasia, and joint destruction, deformity and loss of function. RA synovitis shows massive leukocyte infiltration, proliferative synovial cells and pannus formation, which are responsible for the cartilage and bone destruction (1). Previous studies have demonstrated that inflammatory cytokines and chemokines play an important role in the pathogenesis of RA (2–4). Transforming growth factor-β (TGF-β) and nuclear factor kappa-B (NF-κB) signaling are crucial regulatory...
pathways in RA (5–7). It is well accepted that the biological activities of TGF-β are mediated through both type I and type II receptors to regulate TGF-β-responsive genes by inducing phosphorylation of two downstream signaling molecules Smad2 and Smad3 (8, 9). In addition, TGF-β also induces Smad7 expression, an inhibitory Smad family member, to negatively regulate TGF-β/Smad signaling via a feedback mechanism (10, 11). However, the regulatory roles of Smad7 in inflammation and autoimmunity are still controversial. It has been shown that disrupted Smad7 promotes renal inflammation and fibrosis via both TGF-β/Smad and NF-κB signaling pathways, which are inhibited by overexpressing renal Smad7 (11–16). It is also reported that Smad7 deficiency increases TGF-β signaling and inhibits T cell activation, while the overexpression of Smad7 enhances the resistance of autoimmune T cells to Treg suppression (17–19). In autoimmune arthritis such as RA, the exact functions of Smad7 remain unexplored. Thus, this study examined the potential roles of Smad7 in synovial tissues from RA patients and in a mouse model of collagen-induced arthritis (CIA) in Smad7 KO CD-1 mice.

RESEARCH DESIGN AND METHODS

Patients
Synovial tissues were obtained from a total of 14 patients. All patients fulfilled the 1987 criteria of rheumatoid arthritis of the American College of Rheumatology (20). Clinically, these RA patients (5 male and 9 female) had the mean age of 50.2 ± 16.8 years and disease duration over 73.8 ± 49.6 months and developed high levels of Disease Activity Score-28 (4.9 ± 0.9), erythrocyte sedimentation rate (64.3 ± 21.9 mm/h), and hs-CRP (24.1 ± 19.3 mg/L). Control synovial tissue specimens were obtained from 5 traumatic patients with knee tear ligament surgery without any evidence of rheumatoid disease (2 males and 3 females; mean age at 41.8 ± 13.5 years). All samples were fixed in formalin for paraffin section or in liquid nitrogen for frozen section. All patients were informed about the aims of specimen collection and given the signed written consent. The study was approved and performed in accordance with the ethical guidelines of Peking University Shenzhen Hospital.

Animal Models and Clinical Parameters
Smad7 knockout (KO) and wild-type (WT) CD-1 male mice were used in this study. Smad7 KO mice were generated by functionally deleting exon 1 in the Smad7 gene as previously described (21). The genotype of Smad7 KO mice was confirmed by PCR with the primers (21). It is well known that the CD-1 mice are an outbred stock. To overcome the genetic heterogeneity of outbred CD-1 mice, all Smad7 KO/WT mice were inbred for at least 20 consecutive generations to obtain their homogenous genetic background. This CD-1 inbred strain was used in this study. We adopted the well-established method of collagen-induced arthritis (CIA) (22, 23) in genetically identical littermate Smad7 KO and WT CD-1 mice (n = 8/group, male, aged 8–10 weeks, 32.29 ± 3.2 g) by intracutaneous injection of the mixture of 100 µl chicken collagen II (5 mg/ml, Sigma, St. Louis, MO, United States) emulsified with the complete Freund’s adjuvant (CFA, 4 mg/ml, Sigma) at the base of the tail. Fourteen days later, these mice received the second immunization of the mixture of collagen II and the incomplete Freund’s adjuvant. Control mice followed the same protocol except they received saline only. In addition, group of 6normal Smad7 WT/KO mice at the same age were used as normal control. All mice were sacrificed at 10 weeks for collecting blood, synovium and joints for disease evaluation. The clinical severity of arthritis was assessed as previously described (24): (0) normal without detectable lesions; (0.5) erythema + edema in only one digit; (1) erythema + mild edema detectable in the footpad or ankle, or two to five digits; (2) erythema + moderate edema detectable in two joints (footpad, ankle), or two to five digits; (3) erythema + severe edema of the entire paw; (4) reduced swelling but deformation with incapacitated limb. Individual score was obtained by two investigators who were unaware of the mouse identity, and the mean value was calculated. All experimental procedures were approved by the Animal Experimentation Ethic Committee at the Chinese University of Hong Kong.

Real-Time PCR
Synovium tissues were collected by carefully removing the bilateral knee joint and they were kept at −80°C freezer before being analyzed of the genes of interest using quantitative real-time PCR as previously described (16). The primers used in this study including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), TGF-β, and the house keeping gene GAPDH as described previously (16), whereas primers for interleukin-6 (IL-6), RORγt, interleukin-17A (IL-17A), Foxp3, interleukin-10 (IL-10), T-bet and GATA-3were described below:

- IL-6 forward: 5-AGGATAACCACCTCCCAACAGACCT-3; reverse: 5-CAAGTGCATCATCGTTGTTCATAC-3;
- RORγt forward: 5-CCGCTGAGAGGGCTTCAC-3; reverse: 5-TGAGGAGTAGGGCCACATTACA-3;
- IL-17A forward: 5-TTTAACTCCCTTGGCGCAAAA-3; reverse: 5-CTTCCCTCCTGGCGATTAAC-3;
- Foxp3 forward: 5-GCACCTCCTCCAAATCCCAAGT-3; reverse: 5-GGCCACCTTGACAGACCAT-3;
- T-bet forward: 5-GCGTCTGATATCGTGTAGGT-3; reverse: 5-GTCCCTGCCGATTCCTC-3;
- GATA-3 forward: 5-ACGGCTTCTGGATGCAA-3; reverse: 5-GCTTTCGCTGGCTTAAAT-3.

House keeping gene GAPDH was used as an internal standard. The ratios of the mRNAs examined against GAPDH were obtained and expressed as mean ± S.E.

Elisa
The ELISA Kit for IL-17A was purchased from R&D (Minneapolis, MN, United States) and ELISA kits for TNF-α, IL-1β and TGF-β were obtained from Santa Cruz (California, USA). Plasma levels of TNF-α, IL-1β, TGF-β and IL-17A were detected by ELISA according to the manufacturer’s protocol. In addition, serum levels of mouse anti-collagen II IgG and subclasses of IgG1 and IgG2a were also measured by ELISA using the ELISA kits obtained from Chondrex, Inc. (Redmond, WA, United States).
Histology and Immunohistochemistry
The pathological changes in synovial tissues and joints were examined in paraffin-embedded tissue sections (4 μm) by hematoxylin-eosin (HE) staining. Immunohistochemistry (IHC) was performed on paraffin sections using the microwave-based antigen retrieval technique. The antibodies used in this study were as followed: CD3, IL-17, IL-6 and Foxp3 (Abcam, Cambridge, United Kingdom), TNF-α, IL-1β, TGF-β, TGF-β receptor II, Smad7 (Santa Cruz, California, United States), F4/80 (Serota, Raleigh, North Carolina, United States), MCP-1 (eBiosience, San Diego, CA, United States), phospho-Smad3 (Rockland, Philadelphia, United States), phospho-p65 (Cell signaling, Beverly, MA, United States), rabbit anti-rat secondary antibody, rabbit anti-goat secondary antibody and anti-rabbit polymer (DAKO, Carpinteria, CA, United States). Expression levels of TGF-β, TGF-β receptor II, Smad7, TNF-α, IL-1β, MCP-1, IL-17, and IL-6 in synovial tissues were analyzed and determined using the quantitative Image Analysis System (AxioVision 4, Carl Zeiss, Germany) as previously described (1). The number of cells positive for phospho-p65, phospho-Smad3, T-bet, Gata3, CD3, and F4/80 were counted in 5 consecutive high power fields (40x) by means of a 0.0625-mm² graticule fitted in the eyepiece of the microscope and expressed as cells per millimeters squared.

Immunofluorescence
Two-color immunofluorescence (IF) was performed on frozen sections with PE-labeled rat anti-mouse CD4, FITC-labeled rat anti-mouse IL-17A, FITC-labeled rat anti-mouse Foxp3, FITC-labeled rat anti-mouse IFN-γ and FITC-labeled rat anti-mouse Gata3 (eBiosience, San Diego, CA, United States). Single, double, or triple positive cells were counted under fluorescent microscope (Axioplan2 imaging, Carl Zeiss, Oberkoche, Germany) in 10 consecutive high-power fields (40x) per section by means of a 0.0625 mm² graticule fitted in the eyepiece of the microscope and expressed as cells per mm².

Statistical Analysis
Data were presented as the mean ± S.E. and statistical significance between groups was assessed with one-way analysis of variance (ANOVA) or two-way ANOVA, followed by Tukey's post-hoc test using the Prism 5.0 GraphPad Software (San Diego, CA, United States).

RESULTS
Smad7 Is Largely Reduced in Synovial Tissues of Patients With RA, Which Is Associated With Enhanced TGF-β/Smad3 Signaling And Th17 And Th1 Responses
To evaluate TGF-β/Smad signaling in RA, synovial tissues from 14 patients with RA were examined by immunohistochemistry and immunofluorescence. Compared to controls, TGF-β/Smad3 signaling was highly activated in the synovial tissues of RA patients as identified by overexpressing TGF-β1, TGF-β receptor II (TβRII), and phospho-Smad3 nuclear translocation (Figures 1A–C). In contrast, expression of Smad7 was largely reduced in the synovial tissues of RA patients (Figure 1D), demonstrating that the imbalance of TGF-β/Smad signaling occurs in RA tissues and that the loss of Smad7 may promote activation of TGF-β/Smad3 signaling and RA inflammation.

Smad7 Deficiency Increases Susceptibility to Autoimmune Arthritis in CD-1 Mice
We next examined T cell immune response in patients with RA by two-color immunofluorescence. As shown in Figure 2, both CD4⁺ IL-17⁺ cells and CD4⁺ Foxp3⁺ cells increased in the synovial tissues of RA patients. However, the number of CD4⁺ IL-17⁺ cells was far excessive than CD4⁺ Foxp3⁺ cells with a 2.7-fold increase in the synovial tissues of RA patients. This strongly suggests that the imbalance of Th17 over the Treg existed in the synovial tissue of patients with RA. Interestingly, two-color immunofluorescence also detected that patients with RA increased both CD4⁺ IFN-γ⁺ and CD4⁺ IL-4⁺ cells in the synovial tissues with more favorable Th1 response over Th2 (ratio Th1:Th2 = 1.58:1) as shown in Supplementary Figure 1.

Smad7 Deficiency Promotes CIA Synovial Inflammation in CD-1 Mice
Since uncontrollable inflammation caused by over-activated immune cells and inflammatory cytokines is a critical motivator in the development of RA, we examined whether Smad7 deficiency promotes joint inflammation. Both immunohistochemistry and real-time PCR detected that synovial inflammation was not evidenced in Smad7 WT mice, but largely developed in Smad7 KO CD-1 mice (75%) developed severe CIA as demonstrated by the severe swollen of ankles and toes (Figures 3A, C and Supplementary Figure 2A). This was associated with synovial hyperplasia, inflammatory cell infiltration, pannus emergence, cartilage and bone erosion (Figures 3B, D–F).
Disrupted Smad7 Alters the Immune-Balance by Promoting Th17 Over Treg Response in CD-1 Mice

It has been shown that enhanced Th17 response is a key mechanism of RA (29, 30). We next examined whether loss of Smad7 promotes Th17 response in CIA. As shown in Figures 5A,B, deletion of Smad7 resulted in a marked increase in CD4⁺IL-17A⁺ cells in the synovial tissues in response to collagen II injection, whereas no Th17 response was evidenced in Smad7 WT mice. Real-time PCR and ELISA also detected that Smad7 KO mice exhibited a marked upregulation of IL-17 mRNA in the diseased joint tissues with elevated plasma levels of IL-17A (Figures 5C,D), demonstrating that the loss of Smad7 triggers the Th17 response in CIA.

We next investigated the potential mechanisms by which deletion of Smad7 promotes Th17 response by studying both TGF-β and IL-6 signaling in the synovial tissues, since TGF-β1, together with IL-6, can promote Th17 response via the orphan nuclear receptor retinoid-related orphan receptor (ROR) γt-dependent mechanism (31, 32). As shown in Figures 6A–D, real-time PCR, immunohistochemistry, and ELISA detected that deletion of Smad7 largely increased TGF-β1 expression both locally in synovial tissues and systemically in plasma, which resulted in the activation of Smad3 signaling as evidenced by a marked increase in phospho-Smad3 nuclear translocation in the diseased joint tissues. Interestingly, real-time PCR also detected that deletion of Smad7 upregulated IL-6 and RORγt mRNA expression in synovial tissues of CIA in CD-1 mice, but not in Smad7 WT-CIA mice (Figures 6E,F). These findings suggest that loss of Smad7 promotes Th17-mediated autoimmune arthritis in CD-1 mice, a mouse strain resistant to the development of CIA.

It is also known that the activation of TGF-β/Smad3 signaling can promote Treg response via a Smad3-dependent mechanism. Indeed, real-time PCR showed that deletion of Smad7 upregulated Foxp3 transcription (Figure 6G) and thus...
increased CD4 Foxp3 Treg cells in the diseased synovial tissues (Figure 7A), suggesting an increased Treg response in Smad7 KO CIA-mice. However, by comparison analysis it clearly demonstrated that disrupted Smad7 significantly altered the balance between Th17 and Treg by a 2.7-fold increase in the ratio of RORyt/Foxp3 mRNA (Figure 6H) and a 3-fold increase in the ratio of CD4 IL-17A/CD4 Foxp3 cells (Figure 7B). Interestingly, deletion of Smad7 promoted an equal Th1 and Th2 immune response locally in the diseased tissues by increasing both Th1 and Th2 master transcriptional factor (T-bet/GATA3) and their signature cytokines IFN-γ and IL-4 (Supplementary Figure 4) without
altering the ratio of CD4⁺ IFN-γ⁺ cells/CD4⁺ IL-4⁺ cells (Supplementary Figures 5, 6). This was also supported by the ELISA finding that deletion of Smad7 resulted in a significant increase of anti-collagen II total IgG and subclasses of IgG1 (Th2-dependent) and IgG2a (Th1-dependent) when compared to Smad7 WT CIA mice (Figure 8). Taken together, these novel findings suggest that disrupted Smad7 increases the susceptibility to CIA by enhancing both Th1 and Th2 response
FIGURE 4 | Deletion of Smad7 largely enhances synovial inflammation and activation of NF-κB signaling in CIA mice. (A) CD3 expression. (B) F4/80 expression. (C) Phospho-IκBα. (D) Phospho-p65. Results show that severe joint inflammation evidenced by many CD3⁺ T cells and F4/80⁺ macrophages and a marked activation of NF-κB signaling developed in Smad7-KO but not in Smad7-WT CIA mice (CD-1 background). Data are expressed as mean ± S.E. for group of 8 mice. ***p < 0.001 vs. control (CTL); ####p < 0.001 vs. WT-CIA group. Scale bar, 50 µm.

and importantly, by triggering the Th17 over the Treg immune response.

DISCUSSION

In the present study, we reported that Smad7 plays a protective role in CIA. This was supported by the finding that loss of Smad7 was associated with a marked activation of TGF-β/Smad signaling and the development of arthritis in patients with RA. Surprisingly, disruption of Smad7 from CD-1 mice, a strain of CIA resistance, greatly promoted the development of autoimmune arthritis including severe swollen of ankles and toes with synovial hyperplasia, massive inflammatory cells infiltration, pannus emergence, and cartilage/bone erosion. Findings from this study revealed a critical role of TGF-β/Smad signaling in the pathogenesis of autoimmune arthritis and identified Smad7 as a negative regulator of autoimmune arthritis.

It is well known that Smad7 is an important inhibitor in the feedback-loop of TGF-β/Smad signaling and also functions as an integrator, not only to block TGF-β/Smad but also to
inhibit NF-κB signaling by inducing a NF-κB inhibitor IKBα (16, 33–35). Thus, disruption of Smad7 not only promotes TGF-β/Smad3 signaling and tissue fibrosis, but also largely enhances NF-κB-driven inflammation in several disease models (36–38).

Consistent with the protective role of Smad7 in tissue fibrosis and inflammation, we found that loss of Smad7 largely enhanced activation of both TGF-β/Smad3 and NF-κB signaling in the synovial tissues in response to CIA. This may well explain why...
deletion of Smad7 promoted autoimmune arthritis in CD-1 mice. In contrast, intraarticular overexpression of Smad7 ameliorates experimental arthritis (39). Thus, Smad7 may function to balance the TGF-β/Smad and NF-κB signaling and hence determines the occurrence and the severity of CIA, as illustrated in this study.

Th17/Treg imbalance has been reported to contribute to a variety of inflammatory autoimmune diseases (29, 40–42). It is reported that active RA patients exhibited hyper-reactive Th17 while decreasing Treg response (40). Interestingly, the present study detected that disruption of Smad7 significantly increased...
Th1, Th2, Th17, and Treg immune responses and production of antigen-specific antibodies including anti-collagen II IgG and subclasses of IgG1 and IgG2a in CIA mice, demonstrating a negatively regulatory role of Smad7 in T cell immunity in response to CIA. It has been reported that Th17 is an effective B cell helper (43) and IL17 has been show to play a regulatory role in antibody production (44). In the present study, we also found that a significant increase in Th17 cells in Smad7 KO mice was accompanied with higher levels of anti-collagen antibodies. It is possible that disrupted Smad7 increased TGF-β signaling and thus promoted Th17-dependent B cell activation and anti-collagen II antibody production as seen in Smad7 KO mice with CIA. In addition, follicular helper T (Tfh) cell is critical for GC formation and antibody production (45) and previous
studies showed that active TGF-β signaling could promote Th cell differentiation (46). In this study, we showed that deletion of Smad7 promoted TGF-β/Smad3 signaling, which might stimulate the Th differentiation and autoantibody production. Thus, it is likely that Smad7 deletion may result in autoantibody overproduction via both Th17 and Th17-dependent mechanisms.

Further studies by using ratio analysis showed that while disruption of Smad7 promoted both Th1 and Th2 equally, excessive Th17 over Treg responses were detected in arthritic joint tissues. Specifically, the intensity of Th17 response was double of that by Treg as evidenced at the levels of transcription (RORγt > Foxp3), cytokines (IL-17A > IL-4), and infiltrating cells (CD4+ IL-17A+ > CD4+ Foxp3+ cells). These observations further revealed that disruption of Smad7 not only promotes T cell immune responses in general, but also causes the imbalance of Th17 over the Treg immune response. It is well documented that TGF-β signaling promotes the differentiation of Treg cells via a Foxp3-dependent mechanism (47), while inducing Th17 differentiation in combination with IL-6 via the RORγt-dependent pathway in patients with RA (48, 49). In this study, we found that Smad7 deficiency largely enhanced TGF-β signaling and IL-6 expression, which may be responsible for the upregulation of RORγt and an increase in Th17 differentiation. IL-17 may mediate tissue inflammation by inducing other pro-inflammatory cytokines (such as IL-6, IL-1β, and TNF-α), which in turn may activate the downstream pathways including NF-κB to further amplify the inflammatory cascade (50–52). By this means, the pro-inflammatory effects of Th17 may override the protective effects of Treg cells. Therefore, increased TGF-β/Smad3 and IL-6 signaling may be a key mechanism through which disruption of Smad7 promotes RORγt-mediated Th17-dependent autoimmune arthritis as seen in this study.

In conclusion, the present study revealed that Smad7 deficiency promoted autoimmune arthritis and enhanced NF-κB activation, Th1/Th17 differentiation and synovial inflammation, which might result from the uncontrollable TGF-β/Smad3-IL-6 signaling due to Smad7 defect. Results from this study suggest that Smad7 may be a novel therapeutic agent for treatment of autoimmune arthritis.

**AUTHOR CONTRIBUTIONS**

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

**FUNDING**

The Shenzhen Science and Technology Program for Basic Research (Grants No.: JCYJ20170307112009204), Traditional Chinese Medicine Bureau of Guangdong Province (Grants No.20183011), Sanming Project of Medicine in Shenzhen (SZSM201612009), National Natural Science Foundation of China (81471601), Research Grants Council of Hong Kong (GRF 14121816 and C7018-16G), and LuiChe Woo Institute of Innovative Medicine (CARE).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2018.02537/full#supplementary-material

**REFERENCES**

1. Matsui T, Nakata N, Nagai S, Nakatani A, Takahashi M, Momose T, et al. Inflammatory cytokines and hypoxia contribute to 18F-FDG uptake by cells involved in pannus formation in rheumatoid arthritis. *J Nucl Med.* (2009) 50:920–6. doi: 10.2967/jnumed.108.060103
2. Yoshida K, Hashimoto T, Sakai Y, Hashirimoto A. Involvement of the circadian rhythm and inflammatory cytokines in the pathogenesis
of rheumatoid arthritis. J Immunol Res. (2014) 2014:282495. doi: 10.1155/2014/282495

3. Mateen S, Zafar A, Moin S, Khan AQ, Zubair S. Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis. Clin Chim Acta (2016) 451:26–31. doi: 10.1016/j.cca.2016.02.010

4. McNees IR, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. (2007) 7:429–42. doi: 10.1038/nri2094

5. Sakuma M, Hatsushika K, Koyama K, Katoh R, Ando T, Watanabe Y, et al. TGF-beta type I receptor kinase inhibitor down-regulates rheumatoid synoviocytes and prevents the arthritis induced by type II collagen antibody. Int Immunol. (2007) 19:117–26. doi: 10.1093/intimm/dxl128

6. Roman-Blas JA, Jimenez SA. NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthr Cartilage (2006) 14:839–48. doi: 10.1016/j.joca.2006.04.008

7. Lee YR, Kweon SH, Kwon KB, Park JW, Yoon TR, Park BH. Inhibition of IL-1beta-mediated inflammatory responses by the Ikkappa beta super-repressor in human fibroblast-like synoviocytes. Biochem Biophys Res Commun. (2008) 379:90–4. doi: 10.1016/j.bbrc.2008.11.002

8. Verrecchia F, Chu ML, Mauckel A. Identification of novel TGF-beta /Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem. (2001) 276:17058–62. doi: 10.1074/jbc.M1075420

9. Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A. Targeted disruption of Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest. (2003) 112:1486–94. doi: 10.1172/jci9270

10. Li JH, Zhu HJ, Huang XR, Lai KN, Johnson RJ, Lan HY. Smad7 inhibits fibroetic effect of TGF-Beta on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol. (2002) 13:1464–72. doi: 10.1016/S0104-6800(02)00825-1

11. Lan HY, Mu W, Tomita N, Huang XR, Li JH, Zhu HJ, et al. Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol. (2003) 14:1555–48. doi: 10.1097/01.ASN.0000090673.04658.BB

12. Huo CC, Wang W, Huang XR, Fu P, Chen TH, Sheikh-Hamad D, et al. Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-beta signaling and fibrosis in rat renal kidney. Am J Pathol. (2005) 166:761–71. doi: 10.1016/S0002-9440(10)62297-3

13. Ng YG, Hou CC, Wang W, Huang XR, Lan HY. Blockade of NFkappaB activation and renal inflammation by ultrasound-mediated gene transfer of Smad7 in rat remnant kidney. Kidney Int Suppl. (2005) S85–91. doi: 10.1111/j.1533-7087.2005.01422.x

14. Ka SM, Huang XR, Lan HY, Tsai PY, Yang SM, Shiu HA, et al. Smad7 gene therapy ameliorates an autoimmune crescentic glomerulonephritis in mice. J Am Soc Nephrol. (2007) 18:1777–88. doi: 10.1681/asn.2006080901

15. Huang XR, Chung AC, Zhou L, Wang XJ, Lan HY. Latent TGF-beta1 protects against crescentic glomerulonephritis. J Am Soc Nephrol. (2008) 19:233–42. doi: 10.1681/asn.2007040484

16. Chung AC, Huang XR, Zhou L, Heuchel R, Lan KN, Lan HY. Disruption of the Smad7 gene promotes renal fibrosis and inflammation in unilateral ureteral obstruction (UUO) in mice. Nephrol Dial Transplant. (2009) 24:1443–54. doi: 10.1093/ndt/gfn469

17. Nakao A, Miike S, Hatano M, Okumura K, Tokuhashi T, Ra C, et al. Blockade of transforming growth factor-beta/Smad signaling in T cells by overexpression of Smad7 enhances antigen-induced airway inflammation and airway reactivity. J Exp Med. (2000) 192:151–8. doi: 10.1084/jem.192.2.151

18. Fantini MC, Rizzo A, Finna D, Caruso R, Sarra M, Stolfi C, et al. Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology (2009) 136:1308–16, e1–3. doi: 10.1053/j.gastro.2008.12.053

19. Kleiter L, Song J, Lukas D, Hasan M, Neumann B, Croxford AL, et al. Smad7 in T cells drives T helper 1 responses in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain. (2010) 133(Pt 4):1067–81. doi: 10.1093/brain/awq069

20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1988 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. (1988) 31:315–24.
44. Ludwig RJ, Vanhoorelbeke K, Leyboldt F, Kaya Z, Bieber K, McLachlan SM, et al. Mechanisms of autoantibody-induced pathology. *Front Immunol.* (2017) 31:603. doi: 10.3389/fimmu.2017.00603
45. Crotty S. T follicular helper cell differentiation, function, and roles in disease. *Immunity* (2014) 41:529–42. doi: 10.1016/j.immuni.2014.10.004
46. Locci M, Wu J, Arumemi F, Mikulski Z, Dahlberg C, Miller AT, et al. Activin A programs the differentiation of human T FH cells. *Nat Immunol.* (2016) 17:976–84. doi: 10.1038/ni.3494
47. Samson M, Audia S, Janikashvili N, Ciudad M, Trad M, Fraszczak J, et al. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. *Arthritis Rheum.* (2012) 64:2499–503. doi: 10.1002/art.34477
48. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. *Eur J Immunol.* (2010) 40:1830–5. doi: 10.1002/eji.201040391
49. Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. *Immunity* (2008) 28:29–39. doi: 10.1016/j.immuni.2007.11.016
50. Chang SH, Dong C. Signaling of interleukin-17 family cytokines in immunity and inflammation. *Cell Signal.* (2011) 23:1069–75. doi: 10.1016/j.cellsig.2010.11.022
51. Kolls JK, Linden A. Interleukin-17 family members and inflammation. *Immunity* (2004) 21:467–76. doi: 10.1016/j.immuni.2004.08.018
52. Gu C, Wu L, Li X. IL-17 family: cytokines, receptors and signaling. *Cytokine* (2013) 64:477–85. doi: 10.1016/j.cyto.2013.07.022

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Zhou, Sun, Qin, Cai, Wang, Lan and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.